MedPath

The OBstetric Lidocaine Patch (OBLido) Trial

Phase 4
Completed
Conditions
Pain, Postoperative
Interventions
Drug: Transdermal Lidocaine Patch
Drug: Transdermal Hydrocolloid Placebo Patch
Registration Number
NCT03810235
Lead Sponsor
University of Wisconsin, Madison
Brief Summary

This study will be a single-center, single blind, randomized controlled trial. The study will be conducted at UnityPoint-Health Meriter Hospital under investigators from the University of Wisconsin-Madison. Obstetric patients with prepregnancy obesity undergoing a Cesarean delivery at UnityPoint-Health Meriter will be eligible.

Detailed Description

The purpose of this study is to determine whether transdermal lidocaine administered at the time of Cesarean delivery and for 12 hours postoperatively will reduce the total dose of opioids received. Our hypothesis is that a lidocaine patch will reduce the total dose of opioids received in the immediate 24 hours post-delivery. Secondary outcomes will include patient self-reported pain scores, patient-reported incidence of side effects, such as pruritis, development of objective complications, such as serious skin reactions (examples are acute generalized exanthematous pustolosis, Stevens-Johnson syndrome, and toxic epidermal necrolysis), hypersensitivity, nausea, and nervousness. Other outcomes collected will include length of stay, time to first rescue analgesic medication, total dose of opioids in 48 hours, use of supplemental oxygen during hospitalization, total dose of opioids during hospitalization, breastfeeding rates, both exclusive and in combination with formula use, amount of opioid prescribed at discharge and whether refills were requested or administered, rates of chronic pain at six weeks postpartum, and six week Edinburgh Depression Screen scores. Neonatal outcomes such as five-minute Apgar scores and development of adverse outcomes will also be collected.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
66
Inclusion Criteria
  • Maternal age greater than or equal to 18
  • Prepregnancy body mass index greater than or equal to 30 kg/m2 or ≥35 kg/m2 at delivery if no prepregnancy/ early pregnancy weight available
  • Singleton or multifetal pregnancy
  • Able to receive neuraxial analgesia
  • Planned/ scheduled Cesarean delivery OR non-urgent Cesarean delivery with adequate time to consider and consent to the study
  • Gestational age greater or equal to 32 weeks
Exclusion Criteria
  • Known hypersensitivity to lidocaine or colloid patch (defined as a history of a reaction or allergy to lidocaine (injectable, intravenous, or transdermal) or hydrocolloid patch reported by patient or documented in the medical record) or patient report
  • Contraindication to regional analgesia
  • Positive urine drug screen at admission to the hospital, if ordered for clinical purposes.
  • Current opioid use or opioid use disorder per patient report or documented in the medical record or the ePDMP (reviewed by PI 1-14 days prior to surgery)
  • Chronic opioid use or opioid use disorder, either patient reported or documented in the medical record or the ePDMP (reviewed by PI 1-14 days prior to surgery), defined as opioid use on most days for >3 months
  • Planned Cesarean hysterectomy (excluded due to anticipated blood loss and alternative pain control measures, possible prolonged intubation)
  • Planned vertical midline incision
  • Presence of renal dysfunction precluding the use of NSAIDs
  • Ischemic heart disease, congestive heart failure, or cardiomyopathy of pregnancy
  • Coagulopathy
  • Planned discharge from the hospital less than 24 hours postpartum

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Transdermal Lidocaine PatchTransdermal Lidocaine PatchDrug: Including placebo The intervention is the post-operative application of a 5% lidocaine transdermal patch for women who have undergone Cesarean delivery.
Transdermal Hydrocolloid Placebo PatchTransdermal Hydrocolloid Placebo PatchDrug: Including placebo The intervention is the post-operative application of a hydrocolloid transdermal patch for women who have undergone Cesarean delivery.
Primary Outcome Measures
NameTimeMethod
Total Dose of Opioids Received in the First 24 Hours Following Cesareanup to 24 hours

The total dose of opioids received in the first 24 hours following Cesarean delivery measured as oral morphine equivalents. This total dose will be calculated for every subject in the study, and the average and standard deviation (or appropriate non-parametric values if the data is not normally distributed) will be compared between the subjects randomized to the intervention arm and the placebo arm of the study.

Secondary Outcome Measures
NameTimeMethod
Post-operative Pain Score at 24 Hours Post-operativelyup to 24 hours

The post-operative pain score at 24 hours post-operatively will be measured using the numeric rating scale (NRS), wherein subjects rate pain on a 0-10 scale (10 meaning the most pain and 0 meaning no pain). The median NRS score at 24 hours will be compared between the two groups.

Trial Locations

Locations (1)

UnityPoint Health-Meriter Hospital

🇺🇸

Madison, Wisconsin, United States

UnityPoint Health-Meriter Hospital
🇺🇸Madison, Wisconsin, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.